骨髄移植

抄録

Forty nine patients, 43 with acute leukemia and 6 with chronic leukemia, were treated with chemotherapy, total body irradiation and bone marrow transplantation from allogeneic or syngeneic donors.
Among 43 patients with acute leukemia, 13 patients were given allogeneic marrow graft at the first complete remission stage and their relapse-free survival and relapse rate were 69.2% and 23.1% respectively. Another eight patients were given allogeneic marrow graft at the second or third remission stage and their relapse-free survival and relapse rate were 37.5% and 37.5% respectively. The remaining 22 patients received allogeneic or syngeneic marrow graft at the time of leukemia relapse and all died within 16 months after the transplantion.
Among six patients with chronic myelogenous leukemia, two patients were given allogeneic marrow graft at the chronic phase and the other four patients received allogeneic marrow graft at the time of blastic crisis, and one out of two patients transplanted at the chronic phase was alive.
Twenty out of 49 patients (40.8%) developed interstitial pneumonitis and 17 out of 20 patients died of this complication. Acute GVHD occurred at 59% of the patients and chronic GVHD developed at 63% of long-term (>100 days) survivors. Relapse-free survival rate of the patients who had experienced chronic GVHD was 62.5%, which was higher than that (20%) of the patients who lacked the sign of GVHD.